
Keywords: cardiovascular disease; obesity; pharmacology; prevention; risk factors; BMI; body mass index; FDA; Food and Drug Administration; GLP; glucagon-like peptide; HbA1c; glycosylated hemoglobin; HDL-C; high-density lipoprotein cholesterol; HR; hazard ratio; h